Dr Reddy's launches new product

Hyderabad-based Dr Reddy's Laboratories has launched Celadrin, a product that helps reduce pain and inflammation in patients with osteoarthritis and other joint-related problems, through an alliance with Cymbiotics, a US-based bio-pharmaceutical company. Celadrin was developed by Imagenetix (IAGX), USA, and is licenced to Cymbiotics Inc.

Commenting on the launch, Satish Reddy, managing director and chief operating officer, Dr Reddy's said, "Dr Reddy's is emerging as the partner of choice for many innovators in healthcare on account of our strong brand equity and extensive reach in the Indian market. Celadrin will enhance the treatment options available to medical practitioners in India."

Bill Spencer, chief executive officer of Imagenetix, said, "Celadrin has been shown to be helpful in reducing pain and inflammation in joint disorders. Celadrin contains a proprietory complex of Cetylated Fatty Acid Esters and Omega-3 Fatty Acids (EPA and DHA) that can be safely used in the treatment of arthritis."